Emmanuel Arinaitwe
ID: UNCST-2021-R011754
|
Measuring imported infections and contributions to local transmission in Uganda and Zimbabwe: Uganda studies
REFNo: HS2048ES
To quantify and characterize imported malaria infections in two border sites in sub-Saharan Africa.
To determine the impact of importation on local transmission and identify appropriate targeted interventions in two border sites in sub-Saharan Africa
|
Uganda |
2022-05-27 18:52:11 |
2025-05-27 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Samuel Davidoff-Gore Asher
ID:
|
Socioeconomic Inclusion of Migrant and Forcibly Displaced Women in Cities in West Africa and the Horn of Africa: What Opportunities and Challenges Exist in a Post-COVID-19 World?
REFNo: SS1300ES
This study seeks to understand what the challenges are across these urban contexts, and how development and humanitarian actors need to adapt their programming approaches along with modus operandi. In particular, it explores the following three levels:
• The gender effects of the COVID-19 pandemic and specific challenges faced by female migrants and forcibly displaced women in terms of access to services and livelihoods depending on the urban context, in West Africa and in the Horn of Africa.
• How donors, humanitarian and development actors, as well as national and local governments, the private sector, and civil society have provided economic and social assistance during the health crisis, to what extent these interventions and policies have addressed the socioeconomic challenges faced by migrant and forcibly displaced women and contributed to gender equality.
• Moving forward, how development actors can work towards better including forcibly displaced and migrant women in recovery efforts and overcome the barriers to their inclusion, and how these initiatives should differ based on the urban context (e.g., capital city; border town; small city).
|
USA |
2022-05-26 9:04:08 |
2025-05-26 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Grace Muzanyi
ID: UNCST-2021-R013731
|
ASSESSMENT OF ISONIAZID HAIR DRUG LEVELS A MONG DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS PATIENTS: A STUDY TO MONITOR EXPOSURE, ADHERENCE AND TREATMENT OUTCOMES
REFNo: HS2231ES
General objective: To assess hair levels of Isoniazid among TB patients as a tool to monitor exposure, adherence and treatment outcomes
Specific objectives
1. To determine the acceptability of hair harvest as a method of therapeutic drug monitoring among TB patients in the context of their life experiences, perspective and culture.
2. To determine how hair drug levels relate to plasma drug levels for a fixed Isoniazid dose of 300mg at the 28th ,56th &192nd reference doses in DOT patients compared to patients on SAT at the time points of weeks 4, 8&26 .
3. To specifically determine the mean lowest hair drug level at which TB sputum culture conver-sion occurs by 8 weeks and adverse drug reactions at 4,8&26 weeks of treatment.
4. To determine how each of the factors: diabetes, age, acetylator status, gender, smoking, weight and alcohol affect hair drug levels at the time point of 8 weeks.
|
Uganda |
2022-05-26 9:02:08 |
2025-05-26 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Fatumah Mirembe
ID:
|
Iron Production Technologies in Butiru, Eastern Uganda: An Archaeometallurgical Investigation
REFNo: SS1299ES
-To examine the types of iron smelting furnaces and tuyere forms at Butiru
-To establish the relationship between iron slags and vegetational changes
-To investigate the rituals associated with iron production at Butiru
-To determine the chronology of Butiru iron production
|
Uganda |
2022-05-26 8:14:11 |
2025-05-26 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Gertrude Nakigozi
ID: UNCST-2023-R007979
|
Long-term impact of universal treatment and dolutegravir on population HIV virologic and incidence outcomes in Africa: The LONGVIEW Study
REFNo: HS2249ES
Aim 1: Assess population-level dynamics of HIV viremia and drug resistance before and after COVID-19 emergence. Longitudinal HIV VLs will be obtained for all HIV-positive RCCS participants from 2013 to 2025. Group-based multi-trajectory analysis will be used to assess VL suppression patterns over time, including durable VL suppression. Deep sequence phylogenetic data will be generated for all viremic participants (>1,000 HIV copies/mL) to assess HIVDR. Bayesian non-parametric methods will be used to assess spatiotemporal trends in viremia and HIVDR. We hypothesize that there will be substantial reductions in durable VL suppression, increases in HIVDR, and emergence of DTG resistance following COVID-19.
Aim 2: Use quantitative and qualitative methods to assess the impact of COVID-19 on HIV treatment seeking, utilization and care provision. We will embed questions on health status, social distancing, and impact of COVID-19 on HIV care utilization, including ART adoption and adherence, in the RCCS survey. Using RCCS survey data collected in 2015-2021, we will identify HIV-positive individuals who are viremic and/or who report interruptions in HIV care and conduct in-depth interviews to assess the extent and nature of ART care disruption, including disruption due to COVID-19 and for other reasons. We will also conduct focus group discussions and in-depth interviews with HIV service providers (e.g., health care workers, pharmacists, and program implementers) to assess the impact of COVID-19 on provision of HIV care and treatment. We hypothesize that COVID-19 will result in substantial and widespread health systems disruptions impacting individual-care seeking and HIV service availability.
Aim 3: Evaluate trends in HIV incidence and transmission risk across the infection and care continuum before and after COVID-19 emergence: We will use longitudinal data from the RCCS to estimate HIV incidence trends at the population-level as well as HIV transmission and acquisition risk within cohabitating sexual partnerships. Deep sequence viral phylogenetic data will be used to reconstruct directed transmission networks and to identify source-recipient transmission pairs with infection timing. These data will be combined with information on diagnosis, ART use, and VL at the estimated time of transmission to determine the attributable fraction of transmissions occurring before and after diagnosis and treatment. We hypothesize that there will be an increase in HIV incidence, primarily due to a loss of durable VL suppression in those already on ART and failure to initiate ART by newly diagnosed cases, following service disruption due to COVID-19.
|
Uganda |
2022-05-26 8:12:30 |
2025-05-26 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|